Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

Dolutegravir 50 mg is registered for use in children weighing 20–40 kg. This approval is based on data from an African paediatric cohort, and no pharmacokinetic data was available from children outside of Africa. This study provides further evidence of the effective use of dolutegravir 50 mg in children weighing 20–40 kg by showing adequate dolutegravir exposure is achieved without safety concerns that concentration data gathered in clinical practice shows adequate concentration levels combined with good safety data in Dutch children.